Federal laboratory scientists have identified a bacterial sample from a Massachusetts patient carrying a resistance gene rarely seen outside one specific group of bacteria, and the finding is notable less for how sick the patient was than for how easily it could have gone undetected. The detection was made through the CDC's Antimicrobial Resistance Laboratory Network and reported in Emerging Infectious Diseases.
The bacterium was Proteus mirabilis, a common cause of urinary tract infections. It came from a urine culture collected in May 2024 from a patient receiving outpatient care and carried the gene blaOXA-23.
One detail runs counter to the alarming framing this kind of story usually receives. The isolate remained susceptible to carbapenems, the powerful antibiotics that the gene is normally associated with resistance to. This was not an untreatable infection.
The Gene and Where It Usually Turns Up
The blaOXA-23 gene encodes an enzyme that can hydrolyze carbapenem antibiotics. The OXA-23-like subgroup is among the most common acquired mechanisms contributing to carbapenem resistance in Acinetobacter baumannii, a bacterium associated with serious infections in hospitals and intensive care units.
Outside that genus, it has been reported only infrequently. In Europe, and particularly in France, blaOXA-23-positive Proteus mirabilis isolates are increasingly reported.
Genetic analysis placed the Massachusetts isolate closely related to OXA-23 producers identified in Europe. The authors framed the finding as evidence that Enterobacterales might serve as a silent reservoir of carbapenemase genes commonly associated with Acinetobacter species.
Carbapenems matter because of their position in the treatment sequence. They are frequently reserved for serious infections when other antibiotics have failed or when an organism is already resistant to several drug classes.
The Detection Problem the Report Highlights
The central concern the CDC authors raise is not this one patient's outcome. It is that this type of organism can slip past standard laboratory testing.
Because the isolate still tested susceptible to carbapenems, routine susceptibility testing would not have flagged it. Beyond that, the report notes that blaOXA-23-carrying Proteus mirabilis can escape detection because phenotypic tests for carbapenemase production have poor sensitivity for it, and because most commercial genetic and rapid tests do not include this target.
That combination means a hospital or commercial laboratory could process the sample, report a susceptible result, and move on. The gene would remain in circulation, invisible to the surveillance systems designed to track it.
A diagnostic algorithm based on antimicrobial susceptibility profiles and phenotypic assays has been developed to improve detection in Proteus species, which is the kind of practical fix this finding argues for. The authors called for "continued vigilance in detecting blaOXA-23 in genera beyond Acinetobacter" to prevent further spread between taxa.
The Limits of a Single Isolate
This is a single isolate from one patient, identified through specialized reference testing that most clinical laboratories do not perform. It is not an outbreak, nor does it describe a spreading infection in Massachusetts or elsewhere.
It also does not mean patients should request different antibiotics or carbapenem testing. Community urinary tract infections are treated by local resistance patterns and clinical guidelines, and most respond to standard first-line drugs.
The relevance for readers is more about the infrastructure that catches these signals. Detections like this one come from a national laboratory network that performs testing beyond what a routine clinical lab does, and its capacity determines whether emerging resistance is spotted early or late.
Separate CDC surveillance has documented shifts in resistance patterns nationally. Among 1,288 carbapenemase-producing carbapenem-resistant Enterobacterales identified between 2016 and 2023, the share carrying blaNDM rose from 5.4 percent to 39.8 percent, while blaKPC fell from 92.8 percent to 53.0 percent. Independent coverage of that analysis noted the increase was most pronounced in E. coli.
Reducing Personal Risk Without Overreacting
The most useful individual contribution remains unglamorous. Taking antibiotics only when a clinician determines they are needed, completing the course as prescribed, and never using leftover or borrowed antibiotics all reduce selective pressure.
Preventing infections in the first place also reduces antibiotic use. For urinary tract infections specifically, that includes adequate fluid intake and prompt evaluation of symptoms rather than waiting.
People with recurrent urinary tract infections, indwelling catheters, or recent hospitalization face a higher risk of infections with resistant organisms, and they benefit most from having cultures sent rather than being treated empirically, since cultures identify the organism and its susceptibilities.
Symptoms that warrant urgent evaluation include fever with flank or back pain, confusion in an older adult, or a urinary infection that does not improve within a couple of days of starting treatment. Those can signal a kidney infection or an organism that is not responding.
The CDC publishes ongoing findings from its antimicrobial resistance laboratory networks, and such detections are reported as they are confirmed.
Key Questions Answered
What did the CDC find? A Proteus mirabilis sample from a Massachusetts outpatient urine culture carrying blaOXA-23, a resistance gene rarely reported outside the Acinetobacter genus.
Was the infection untreatable? No. The isolate remained susceptible to carbapenems. The significance lies in the presence of the gene and the difficulty of detecting it, not in this patient's treatment.
Why is the gene concerning? It produces an enzyme that can break down carbapenems, antibiotics often reserved for serious infections when other options have failed.
Why might routine tests miss it? The organism can be tested for susceptibility on standard panels; phenotypic carbapenemase tests have poor sensitivity for it, and most commercial genetic tests do not include this target.
Is this an outbreak? No. It is a single isolate identified through testing at a specialized reference laboratory. It does not describe the ongoing spread.
Should patients change anything? No. Community urinary tract infections are treated according to local resistance patterns and guidelines, and most respond to standard first-line antibiotics.
How can individuals help limit resistance? Take antibiotics only when a clinician determines they are needed, complete the prescribed course, and never use leftover or borrowed antibiotics.
